Cessatech expects to report on its bioavailability trial 0204 within a few weeks
Topline results of clinical trial 0204 in healthy volunteers investigating the absolute bioavailability of CT001, which was set to be announced last month, will be announced in a few weeks. Primary aim of the trial is to investigate drug-exposure following nasal administration of CT001 relative to the IV injection of approved drug counterpartsCessatech A/S announces that the results of the bioavailability trial (0204) has been slightly delayed and will be announced within a few weeks. The trial includes adult healthy volunteers in a randomised three-treatment, three-period, single dose